Neoadjuvant Immunochemotherapy for Lung Cancer
Completed
- Conditions
- Lung Cancer
- Interventions
- Drug: Neoadjuvant immunochemotherapy
- Registration Number
- NCT06023797
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Brief Summary
We retrospectively analyzed lung cancer patients who had NAICT and surgery in the Department of Thoracic Surgery, Zhongshan Hospital. NAICT was defined as chemotherapy that included at one application of PD-1 inhibitor.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 83
Inclusion Criteria
- Lung surgery was performed in the Department of Thoracic Surgery at Zhongshan Hospital;
- At least one cycle of neoadjuvant treatment containing the immune drug PD-1 immunosuppressant was performed before surgery;
- Malignancy was present and confirmed in the pathology before treatment and after surgery;
- The lung lesion was the primary lesion.
Exclusion Criteria
- No lung surgery was performed until 2022.11;
- No preoperative neoadjuvant therapy was performed or recorded;
- Neoadjuvant therapy did not include immune drugs;
- Previous history of malignancy (including surgery and adjuvant therapy);
- Previous use of system-related immune medicines, such as immunosuppressants and monoclonal antibodies; and 6. Other conditions inappropriate for enrollment by the investigator.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description MAICT Neoadjuvant immunochemotherapy chemotherapy that included at one application of PD-1 inhibitor
- Primary Outcome Measures
Name Time Method Progression-free survival (PFS) 2017-2023 Progression-free defined as status of recurrence of lung cancer
Overall survival (OS) 2017-2023 Overall defined as the living status, alive or dead
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Zhencong Chen
🇨🇳Shanghai, Shanghai, China